Joint Formulary & PAD

Tranexamic acid - Fibrinolysis

You are here : Home > Formulary Search > Tranexamic acid - Fibrinolysis

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

Green
Formulations :
  • Tablets
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
SPC
Restrictions / Comments :
 

Status 2

Red
Formulations :
  • Injection
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
SPC
Restrictions / Comments :
 

Status 3

Non Formulary
Formulations :
  • Capsules
Formulary Status :
Primary Care
ASPH
RSFT
SASH
SABP
Associated Icons :
NFD1
SPC
Restrictions / Comments :

Documentation

  • No records returned.

PAD Profile

ChemicalSubstance :
Tranexamic acid
Indication :
Fibrinolysis
Group Name :
Keywords :
menorrhagia, heavy mentrual bleeding, hereditary angioedema, epistaxis, nose bleeds
Brand Names Include :
Cyklokapron
Important Information :
Includes menorrhagia, epistaxis and local fibrinolysis
Latest Additions Date From :
Latest Additions Date To :
Guidelines :
Supporting Documents :
0
Traffic Light Entries :
3

Committee Recommendations (1)

03 May 17 - Surrey & North West Sussex Area Prescribing Committee (formerly Prescribing Clinical Network)
Tranexamic acid has been considered by the PCN and has been assigned a GREEN traffic light status, within its LICENSED indication(s).

NOTE - the branded product (Cyklokapron) was considered BLACK at the PCN in May 2017.

Other Indications

Below are listed other indications that Tranexamic acid is used to treat.

Other Drugs

Below are listed other drugs that are used to treat Fibrinolysis.

  • No records returned.